Related by context. All words. (Click for frequent words.) 81 HBeAg positive chronic hepatitis 80 HBeAg positive 70 HBeAg + 67 HBeAg negative 67 stage IIIB 67 nucleoside naive 67 relapsed MM 67 HBeAg 66 Cell Non Hodgkin 66 micafungin 66 T2DM 66 J Pediatr Orthop 65 Telintra 65 genotype 1a 65 galiximab 65 Epratuzumab 65 leukemia CLL 64 HIV coinfected 64 HCV SPRINT 64 cell malignancies 64 tocilizumab 63 DISCUSSION AND POSSIBLE APPROVAL 63 lamivudine refractory patients 63 mildly symptomatic 63 Aflibercept 63 riociguat 63 trastuzumab Herceptin ® 63 cirrhotic CHC monoinfected patients 63 ROCKET AF 63 RAF kinase 63 genotypic resistance 63 PegIFN RBV 63 HBV genotype 63 decompensated liver disease 63 uncomplicated influenza 63 invasive candidiasis 63 Kinoid 62 completely resected 62 GAMMAGARD S 62 null responder 62 APTIVUS r 62 MVA MUC1 IL2 62 LymphoStat B belimumab 62 K ras mutations 62 PEG IFN 62 constipation predominant irritable bowel 62 Nucleoside 62 precursor acute lymphoblastic 62 DEB# 62 NF Kappa 62 ribavirin therapy 62 leukemia AML 62 AA Amyloidosis 62 unresectable stage 62 HCV infected 62 CCR5 tropic HIV 62 Subgroup analysis 62 ritonavir boosted 62 somatostatin analog 62 stage IIIb IV 62 imatinib therapy 62 nucleoside analogue 62 liposomal amphotericin B 62 recurrent glioblastoma multiforme 62 diarrhea predominant irritable 62 protease inhibitor PI 62 HBeAg negative patients 62 relapsing remitting MS RRMS 62 liver histology 62 ovarian cancer chronic hepatitis 62 posaconazole 62 leukemia ALL 62 antiretroviral naïve 62 cell chronic lymphocytic 62 lymphocytosis 62 Peginterferon Alfa 2a 61 virological response 61 mRCC 61 Chronic Hepatitis C 61 singer Angela Bofill 61 HIV HCV coinfected 61 neurological manifestations 61 CANCIDAS 61 RhuDex TM 61 Haemophilus influenza type 61 PROSTVAC VF 61 BARACLUDE ® 61 AML MDS 61 tipranavir ritonavir 61 metastatic malignant melanoma 61 TMC# r 61 MAGE A3 ASCI 61 T#I [002] 61 blinded randomized placebo controlled 61 methotrexate therapy 61 chronic HCV infection 61 NSABP B 61 chronic HBV 61 virologic response 61 SSc 61 hepatocellular carcinomas 61 gemcitabine carboplatin 61 pegylated liposomal doxorubicin 61 lupus anticoagulant 61 null responder HCV 61 CIMZIA ™ 61 hepatic fibrosis 61 chronic hepatitis B 61 Pregnancy Category 61 Atypical Hemolytic Uremic Syndrome 61 ribavirin RBV 61 mg Proellex 61 AGILECT R 61 enfuvirtide 61 IFN α 60 Relapsed Refractory 60 asymptomatic metastatic 60 antiretroviral naive 60 Bezielle 60 Clemens Injections 60 CYT# potent vascular disrupting 60 PRTX 60 diarrhea predominant IBS 60 T1c 60 HLA DRB1 * 60 caspofungin 60 canakinumab 60 Naive Patients 60 nucleoside analog 60 e antigen HBeAg 60 HCV genotype 60 virologic responses 60 Chronic Hepatitis 60 HIV uninfected 60 HBeAg seroconversion 60 prucalopride 60 Tipranavir 60 lenalidomide Revlimid R 60 CIMZIA TM certolizumab pegol 60 relapsed AML 60 bendamustine 60 castration resistant prostate cancer 60 TMC# C# 60 treatment naïve genotype 60 mcg BID 60 Myelodysplastic Syndrome MDS 60 neurokinin 60 constipation predominant IBS 60 indolent follicular non 60 CD# mAb 60 LHRH receptor positive 60 certolizumab 60 HeFH 60 PEGINTRON TM 60 Castration Resistant Prostate Cancer 60 Leukemias 60 certain NF kappa 60 beta 1a 60 8mg/kg 60 abacavir Ziagen 60 Pooled Analysis 60 CLL SLL 60 vitamin folic acid 60 Xanafide 60 IV NSCLC 60 RRMS patients 60 CTAP# Capsules 60 treatment naive genotype 60 rituximab refractory 60 lupus nephritis 60 Flu Cy 60 VFEND 60 metastatic RCC 60 cytopenias 60 prostate cancer CaP 60 EGFR TKI 59 mCRC patients 59 NRTI resistance 59 metastatic hormone refractory 59 HLA A2 59 receptor tyrosine kinase inhibitor 59 RezularTM 59 divalproex sodium 59 polymerase inhibitor 59 relapsing multiple sclerosis 59 combination antiretroviral therapy 59 visilizumab 59 gemcitabine Gemzar ® 59 YONDELIS 59 Apolipoprotein 59 nonalcoholic steatohepatitis NASH 59 CCR5 receptor antagonist 59 activin 59 Randomized Phase 59 PEGylated interferon beta 1a 59 antiangiogenic therapy 59 Copegus ribavirin 59 teriflunomide 59 syndrome IBS 59 TNF antagonist 59 advanced hepatocellular carcinoma 59 BARNES GROUP 59 Peginterferon 59 evaluating tivozanib 59 Amgen Neulasta R 59 NNRTI resistance 59 weekly subcutaneous injections 59 NNRTI resistant virus 59 idarubicin 59 AVOREN 59 previously untreated follicular 59 ALT elevations 59 Multiple Myeloma MM 59 HBeAg positive patients 59 stage IIIA 59 Pemetrexed 59 Acute Myeloid Leukaemia AML 59 CCR5 antagonist 59 idiopathic Parkinson disease 59 interferon gamma 1b 59 cisplatin gemcitabine 59 virus HCV infection 59 argatroban 59 elevated ALT 59 Teriflunomide 59 EGFR mutations 59 histologically confirmed 59 ErbB2 positive 59 Antiviral Therapy 59 chronic HCV 59 candidemia 59 plus COPEGUS 59 Nilotinib 59 erlotinib Tarceva ® 59 diabetes mellitus DM 59 cell lymphoma DLBCL 59 Virologic 59 coinfected patients 59 randomized multicenter trial 59 demonstrated antitumor activity 59 Soft Tissue Sarcoma 59 alfa 2a 59 dose escalation phase 59 psoriatic arthritis PsA 59 hnRNP 59 ACTEMRA TM 59 thalidomide Thalomid 59 stage IIIb 59 triciribine phosphate monohydrate 59 CP CPPS 59 docetaxel Taxotere ® 59 unfavorable cytogenetics 59 Hepatotoxicity 59 Waldenstrom macroglobulinemia 59 antibody MAb 59 cell acute lymphoblastic 59 β2 58 gastric adenocarcinoma 58 pan HDAC inhibitor 58 LEXIVA r 58 huN# DM1 58 Thiazolidinediones 58 adriamycin 58 lumiliximab 58 refractory chronic lymphocytic 58 dose escalation clinical 58 baminercept 58 plasma pharmacokinetics 58 eosinophilic asthma 58 Subtype 58 follicular Non Hodgkin 58 refractory NSCLC 58 CALGB # [002] 58 Randomised 58 Non inferiority 58 heavily pretreated patients 58 formerly LymphoStat B 58 coinfected 58 Blinatumomab 58 histological subtype 58 denileukin diftitox 58 sargramostim 58 BRAF V#E 58 seropositivity 58 Myelofibrosis 58 AEGR 58 Severe Primary IGFD 58 interferon alfa 58 fluconazole resistant 58 Pegasys peginterferon alfa 2a 58 MCyR 58 GOUT 58 HGS ETR2 58 hormone refractory 58 myelodysplastic myeloproliferative diseases 58 heavily pretreated 58 tipranavir r 58 de novo AML 58 viral kinetics 58 Fibrillex TM 58 Randomized Phase II 58 multicenter randomized placebo controlled 58 #q# deletion syndrome 58 Stage IIIb 58 Vidofludimus 58 EndoTAGTM 1 58 metastatic renal cell carcinoma 58 metastatic malignant 58 davunetide intranasal AL 58 relapsing MS 58 SCIg 58 TO AVOID PREGNANCY WHILE 58 dasatinib Sprycel 58 multicenter phase 58 haemophilus influenzae type 58 elacytarabine 58 doxorubicin cyclophosphamide 58 CC genotype 58 Nonalcoholic fatty liver 58 IBS C 58 solithromycin 58 pyridostigmine 58 Azacitidine 58 basal cell carcinoma BCC 58 tramiprosate Alzhemed TM 58 HQK 58 ACZ# 58 antithrombin III 58 Bortezomib 58 sorafenib Nexavar 58 Kahalalide F 58 interferon IFN 58 BENLYSTA TM 58 evaluating Actimmune 58 5-FU/LV 58 heterozygotes 58 receiving VICTRELIS 58 RhuDex ® 58 pT2 58 Traficet EN 58 Oral Fingolimod 58 Plicera 58 darunavir ritonavir 58 familial amyloidotic polyneuropathy FAP 58 PROSTVAC ® 58 KRAS mutant tumors 58 anti leukemic 58 OF RESOLUTION NO 58 lamivudine resistant 58 ceftazidime 58 pediatric acute lymphoblastic 58 serum leptin 58 CCX# B 58 superinfection 58 Lymphocytic 58 Valdoxan 58 hepatitis C genotype 58 receptor inhibitor 58 Doxil ® 58 Akt inhibitor 58 PKC# 58 follicular lymphomas 58 pegylated interferon alpha 58 baseline FEV 58 Navelbine ® 58 NNRTIs 58 DAPT 58 Dasatinib 58 Systemic Sclerosis 58 rubella hepatitis 58 paclitaxel poliglumex 58 apolipoprotein 58 HBV infections 58 Chronic Hepatitis B 58 Cutaneous T 58 clade B 58 GSK# [001] 58 pomalidomide 58 antiandrogens 58 NPM1 mutations 58 abacavir lamivudine 58 trabectedin 58 methotrexate monotherapy 58 seronegative 58 chronic hepatitis B. 58 Non Alcoholic Steatohepatitis 58 APTIVUS R 58 chronic HCV genotype 58 gefitinib Iressa 58 estramustine 58 vidofludimus 58 cis retinoic acid 58 aminotransferase levels 58 Niemann Pick type 58 JAK2 V#F 58 erlotinib Tarceva 58 ß blockers 58 Adjuvant chemotherapy 58 Procoralan 58 Adalimumab 58 temsirolimus 58 mg BID 58 patientswith 58 Fludarabine 58 Hormone Refractory Prostate Cancer 58 HCV RESPOND 2 58 Cariprazine 58 CAMMS# 58 regulate NF kappa 58 grade cervical intraepithelial 58 dosing cohort 58 elvucitabine 58 PsA 57 recurrent glioblastoma 57 lymphopenia 57 autoantibody positive 57 tarenflurbil 57 Natalizumab 57 ER CHOP 57 headache abdominal pain 57 hepatoma 57 HER2 expression 57 bleomycin 57 hypomethylating agents 57 Haemophilus 57 genotype 1b 57 CIMZIA TM 57 Cloretazine 57 pentoxifylline 57 genotypic 57 BRAF V#E mutation 57 prostate cancer HRPC 57 PEGylated Fab fragment 57 Relapsing Remitting Multiple Sclerosis 57 Peg IFN 57 beta carotene supplementation 57 PSMA ADC 57 cancer mCRC 57 LTBI 57 haemophilus influenza type 57 missense mutation 57 Golimumab 57 Initiated Phase 57 Gleevec resistant 57 ara C 57 Hemophilia B 57 tipranavir 57 thromboembolic complications 57 cetuximab Erbitux R 57 minimally symptomatic 57 Chronic lymphocytic leukemia 57 biliary tract cancer 57 refractory CLL 57 P aeruginosa 57 biochemical relapse 57 lymphoproliferative disorders 57 VICTRELIS 57 valopicitabine 57 elevated LDH 57 Hodgkin lymphoma HL 57 Complicated Skin 57 aminotransferases 57 NMIBC 57 influenzae 57 CR nPR 57 Safinamide 57 undetectable HBV DNA 57 haematologic 57 hypophosphatemia 57 Symadex 57 KRAS wild 57 androgen deprivation 57 Research Bangladesh ICDDR 57 relapsed ovarian cancer 57 immunomodulatory therapy 57 Janus kinase 57 plus DOXIL 57 prostate cancer PCa 57 Lenalidomide 57 adjunctive placebo 57 melphalan prednisone 57 refractory metastatic 57 highly selective endothelin 57 YONDELIS R 57 oral Hycamtin 57 Aplidin 57 MELAS 57 lymphoid malignancies 57 ertapenem 57 velafermin 57 ALT flares 57 Lipodystrophy 57 5alpha reductase 57 Immunotherapeutic 57 Zavesca ® 57 benign prostatic hypertrophy BPH 57 C. trachomatis 57 cariprazine 57 chronic constipation CC 57 alefacept 57 sitaxsentan 57 bexarotene 57 Daclizumab 57 standard chemotherapy regimen 57 HCV replicon 57 Lymphocyte 57 visceral metastases 57 HER2 overexpression 57 prostate cancer CRPC 57 Controlled Trial 57 Decitabine 57 Sunpower Corp Class 57 umol L 57 adjuvant tamoxifen 57 ofatumumab HuMax CD# 57 CsA 57 locoregional 57 receptor blocker 57 induce orthostatic hypotension 57 fluoropyrimidine 57 refractory cutaneous T 57 postmenopausal osteoporotic women 57 decompensated cirrhosis 57 ELISPOT 57 sorafenib Nexavar ® 57 efalizumab 57 peginterferon alfa 2a Pegasys 57 intravenous cyclophosphamide 57 anemia neutropenia 57 acute humoral rejection 57 cell lymphoma CTCL 57 CHOP chemotherapy 57 humanized interleukin 6 57 EDEMA3 57 Arranon 57 relapsed refractory multiple myeloma 57 RhuDex ™ 57 Neuvenge 57 MMSE score 57 relapsed SCLC 57 CDK inhibitor 57 Granulocyte Colony Stimulating Factor 57 carcinoid syndrome 57 UGT#A# * 57 selective modulator 57 mCRPC 57 J Am Soc 57 Chronic lymphocytic leukemia CLL 57 PREZISTA ritonavir 57 ibandronate 57 Elitek 57 endothelin receptor 57 MGd 57 Voreloxin 57 sustained virological response 57 dyslipidaemia 57 serogroup 57 CR CRu 57 transaminase elevations 57 MGUS 57 coinfection 57 ISTODAX ® 57 IIIA NSCLC 57 FOLFIRI 57 PBMCs 57 Randomized Study 57 paricalcitol 57 isoenzyme 57 HCV genotype 1 57 relapsed Acute Myeloid 57 relapsed refractory 57 Phase 1a clinical 57 dasatinib Sprycel ® 57 myeloproliferative diseases 57 Neoadjuvant 57 ocrelizumab 57 Neovascular AMD 57 DLTs 57 PAOD 57 papillary renal cell carcinoma 57 Subphase 57 CIN2 + 57 EOquin TM phase 57 Denufosol 57 nonmetastatic 57 tegaserod 57 immunocompetent 57 bowel syndrome IBS 57 bladder carcinoma 57 vWD 57 cells uL 57 registrational clinical 57 postoperative chemotherapy 57 μmol L 57 omega interferon 57 apolipoproteins 57 Genotypes 57 Pradefovir 57 replicon 57 HBV genotypes 57 chronic HBV infection 57 Androgen Receptor 57 mycophenolate mofetil 57 INSPIRE Trial Phase III 57 sodium glucose cotransporter 56 efavirenz EFV 56 virologic failure 56 triiodothyronine 56 osteopenic 56 Double Blind Randomized 56 Relapsing Multiple Sclerosis 56 idiopathic PAH 56 nucleotide analogs 56 Enzastaurin 56 K#N 56 serologic 56 Alemtuzumab 56 prostate carcinoma 56 cytomegalovirus infection 56 IFN alfa 56 RAPTIVA 56 mycosis fungoides 56 H. influenzae 56 splenectomized patients 56 pneumoniae 56 achieve sustained virologic 56 liver metastasis 56 heFH 56 Antiangiogenic 56 vismodegib 56 pegylated interferon alfa 56 Heterozygous Familial Hypercholesterolemia 56 DDP# 56 vinca alkaloid 56 interleukin IL -# 56 Morquio 56 Cell Lymphoma CTCL 56 Hypoactive Sexual Desire Disorder 56 CML CP 56 receptor antagonists 56 Thiovir 56 axitinib 56 landmark ATHENA 56 glatiramer acetate 56 hematopoietic cancers 56 Hepatitus 56 mixed hyperlipidemia 56 essential thrombocythemia ET 56 pheochromocytoma 56 neuropsychiatric symptoms 56 mapatumumab 56 Follicular Lymphoma 56 Ozarelix 56 low dose cytarabine 56 Trastuzumab 56 peripheral blood mononuclear 56 underwent resection 56 Xelox 56 JAK inhibitors 56 ankylosing spondylitis AS 56 mg/m2 dose 56 nilotinib Tasigna 56 bortezomib Velcade R 56 Rheumatoid Arthritis RA 56 rapid virologic response 56 dosage regimens 56 UPLYSO 56 unresectable tumors 56 colorectal adenocarcinoma 56 Hennekens CH 56 LAS# [002] 56 histologically proven 56 plus prednisone prednisolone 56 Metastatic breast cancer 56 epithelial tumors 56 LHRH agonists 56 Velcade bortezomib 56 chlorambucil 56 docetaxel chemotherapy 56 malignant lymphoma 56 euthymic patients 56 gastrointestinal stromal tumor GIST 56 Helicobacter pylori eradication 56 MabCampath 56 elevated serum creatinine 56 liver transplantations 56 placebo dexamethasone 56 Chronic Myeloid Leukemia 56 phase IIb study 56 sJIA 56 mucosal healing 56 DermaVir Patch 56 HDL cholesterol HDL 56 fluorouracil leucovorin 56 ULORIC 56 tigecycline 56 metastatic neuroendocrine tumors 56 HER2 positive metastatic breast 56 inhibin 56 LB# [003] 56 spud #-#-# drlg [003] 56 achieved sustained virological 56 Cethromycin 56 IMiDs ® compound 56 IL#B 56 ADPKD 56 randomized Phase 2b 56 del 5q 56 % CI #.#-#.# [003] 56 neuroleptic 56 daunorubicin 56 FluCAM arm 56 HuMax EGFr 56 immunopathology 56 decitabine 56 Philadelphia Chromosome Positive 56 antiarrhythmic 56 Epstein Barr virus EBV 56 Advanced Melanoma 56 PRT# 56 pT3 56 HER pathway 56 Verstovsek 56 secondary hyperparathyroidism SHPT 56 β thalassemia 56 Elacytarabine 56 fibromyalgia syndrome 56 multicentre randomized 56 Enzyme Replacement Therapy 56 SGPT 56 lumbar spine BMD 56 B CLL 56 rilonacept 56 syngeneic 56 sunitinib Sutent 56 pDCs 56 gastrin analogue TT 56 chemoradiotherapy 56 CHAMPION PCI 56 sunitinib Sutent ® 56 #.# FM WLKM 56 interferon therapy 56 pamidronate 56 Bayer HealthCare Onyx Pharmaceuticals 56 pradefovir 56 nucleoside analogues 56 metastatic colorectal carcinoma 56 CTEPH 56 atypical hemolytic uremic syndrome 56 targeting CD# 56 ADP receptor antagonist 56 C#BL 6 mice 56 Respiratory Syncytial Virus RSV 56 inactivated hepatitis 56 Oral Surg 56 Fingolimod 56 fosbretabulin 56 4mg/kg 56 Plaque Psoriasis 56 Campath alemtuzumab 56 Pimavanserin 56 E1 INT TM 56 TNF α 56 TKI therapy 56 Generalised Anxiety Disorder 56 relapsed myeloma 56 RhuDex R 56 receptor PAM 56 hypereosinophilic syndrome 56 Therapeutic Vaccine 56 Omacetaxine 56 histologies 56 remission induction 56 serum urate levels 56 overactive bladder syndrome 56 herpes zoster shingles 56 adalimumab 56 metastatic GIST 56 Degarelix 56 oral ridaforolimus 56 Diffuse Large B 56 orally administered inhibitor 56 COPEGUS R 56 Bipolar Mania 56 cystatin 56 satraplatin Phase 56 proctitis 56 clinically meaningful improvement 56 castrate resistant prostate cancer 56 urothelial bladder cancer 56 Quinamed 56 sCD# 56 DAS# CRP 56 cytokine refractory 56 Certolizumab pegol 56 DLBCL 56 chemotherapy cisplatin 56 metastatic gastric 56 lysosomal enzyme iduronate 56 Sipuleucel T 56 plus prednisone 56 Prulifloxacin 56 post herpetic neuralgia PHN 56 doripenem 56 adecatumumab 56 GH deficiency 56 FDG uptake 56 pDC 56 placebo controlled clinical 56 IV metastatic melanoma 56 hemorrhagic cystitis 56 dacetuzumab 56 homozygotes 56 tumors GIST 56 Berinert 56 isoprostane 56 Aplidin R 56 virus HCV 56 oral talactoferrin 56 mcg albinterferon alfa 2b 56 Glioblastoma Multiforme 56 chronic ITP patients 56 simplex virus 56 anti arrhythmic drug 56 refractory acute myeloid 56 Acute Coronary Syndromes ACS 56 germline mutation 56 Elvitegravir 56 serovar 56 CALGB 56 anemia hemoglobin 56 Idiopathic pulmonary fibrosis 56 refractory anaplastic astrocytoma 56 mg kg dose 56 HuMax CD# 56 MVA HPV IL2 56 macroalbuminuria 56 H pylori 56 prospectively defined 56 lymphocyte counts 56 Parkin DM 56 jejuni 56 MADRS score 56 active ankylosing spondylitis 56 sustained virologic response 56 migraine prophylaxis 56 rituximab Rituxan 56 IFN beta 56 Malignant Melanoma 56 tumor xenograft models 56 panitumumab Vectibix 55 titrated glipizide 55 J Clin Oncol 55 genotype 55 myeloproliferative neoplasms 55 RECORD1 55 pulmonary hypertension PH 55 dopaminergic therapy 55 diabetic kidney 55 prognostic indicators 55 operable breast cancer 55 unfractionated heparin UFH 55 CYP #D# 55 irbesartan 55 invasive fungal infections 55 Pralatrexate 55 Romidepsin 55 Nexavar sorafenib 55 IPL# 55 pancreatic insufficiency 55 cinacalcet 55 IgG antibody 55 essential thrombocythemia 55 L methionine 55 Subgroup analyzes 55 Gen Intern Med 55 Engerix B 55 PEG interferon 55 untreated CLL 55 recurrent NSCLC 55 Bronchiectasis 55 NATRECOR ® 55 hA# 55 enteroviral infection 55 prospective randomized placebo 55 splenectomized 55 Generalized Anxiety Disorder 55 MULTAQ 55 lopinavir r 55 oblimersen 55 fludarabine cyclophosphamide 55 invasive aspergillosis 55 fluoxetine paroxetine 55 idiopathic thrombocytopenic purpura ITP 55 Ocrelizumab 55 neuroregenerative 55 Improved Survival 55 Elocalcitol 55 Tarceva TM 55 DAS# remission 55 Chronic Lymphocytic Leukemia 55 recurrent malignant glioma 55 squamous histology 55 ovarian carcinoma 55 thyrotoxicosis 55 potent antiretroviral therapy 55 alkylating agent 55 seropositive patients 55 elotuzumab 55 LPS induced 55 virus HBV 55 achieved sustained virologic 55 Phase IIA 55 ORENCIA ® 55 androgen independent 55 chronic hepatitis C 55 Schizoaffective Disorder 55 SJIA 55 YERVOY 55 Vectibix monotherapy 55 landmark ATHENA trial 55 Reverset 55 chronic lymphocytic leukemia CLL 55 DOXIL 55 Index CDAI 55 Virulizin ® 55 NAbs 55 Vitaxin 55 metastatic kidney 55 P. ovale 55 Sezary syndrome 55 primary aldosteronism 55 Cardiotoxicity 55 Trandolapril 55 colon carcinoma 55 tumor lysis syndrome 55 LV dysfunction 55 double blinded placebo 55 Am Med Assoc 55 effector function 55 superficial bladder cancer 55 Sebivo 55 cathepsin 55 Overactive Bladder 55 Tyrima 55 cilengitide 55 goserelin 55 gastric atrophy 55 acute leukemias 55 CYP #A# 55 mcg dose 55 Carfilzomib 55 gene polymorphism 55 Artesunate 55 nonalcoholic steatohepatitis 55 retrospective cohort 55 chronic Hepatitis B 55 SHPT 55 DFMO 55 SNT MC# 55 octreotide 55 SCCHN 55 VELCADE melphalan 55 Sudhir Agrawal D.Phil 55 chronic granulomatous disease 55 nab paclitaxel 55 overt hypothyroidism 55 H. pylori eradication 55 β blockers 55 AST ALT 55 null mice 55 Phase Ib clinical 55 liver transplant recipients 55 lipid abnormalities 55 GABHS 55 JVRS 55 KRAS status 55 BENICAR HCT 55 lactis 55 HCV Genotype 55 Hepatocellular Carcinoma HCC 55 Streptococcus pneumonia 55 imatinib Gleevec ® 55 HuMax CD4 55 flavopiridol 55 CRp 55 immunoglobulin Ig 55 TEAEs 55 small lymphocytic lymphoma 55 virological failure 55 pharmacologic intervention 55 G#DT 55 Chronic Prostatitis 55 refractory multiple myeloma 55 lymphocyte activation 55 = #.#-#.# 55 PCa 55 TORISEL 55 MEND CABG